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We report the 30-yr history of a well-documented human case of alveolar echinococcosis, with a lung lesion at
presentation followed by the discovery of a liver lesion, both removed by surgery. Subsequently, within the
13 years following diagnosis, metastases were disclosed in eye, brain and skull, as well as additional lung lesions.
This patient had no immune suppression, and did not have the genetic background known to predispose to severe
alveolar echinococcosis; it may thus be hypothesized that iterative multi-organ involvement was mostly due to the
poor adherence to benzimidazole treatment for the first decade after diagnosis. Conversely, after a new alveolar
echinococcosis recurrence was found in the right lung in 1994, the patient accepted to take albendazole
continuously at the right dosage. After serology became negative and a fluoro-deoxy-glucose-Positron Emission
Tomography performed in 2005 showed a total regression of the lesions in all organs, albendazole treatment could
be definitively withdrawn. In 2011, the fluoro-deoxy-glucose-Positron Emission Tomography showed a total absence
of parasitic metabolic activity and the patient had no clinical symptoms related to alveolar echinococcosis.
The history of this patient suggests that multi-organ involvement and alveolar echinococcosis recurrence over time
may occur in non-immune suppressed patients despite an apparently “radical” surgery. Metastatic dissemination
might be favored by a poor adherence to chemotherapy. Combined surgery and continuous administration of
albendazole at high dosage may allow alveolar echinococcosis patients to survive more than 30 years after
diagnosis despite multi-organ involvement.Introduction
Alveolar Echinococcosis (AE) caused by the metacestode
of the “fox tapeworm” Echinococcus (E.) multilocularis is
one of the most lethal helminthic diseases in humans
[1,2]. Humans become infected through contact with
eggs (oncospheres) present in the feces of the definitive
hosts, most often foxes or dogs, but also wolves and
cats, by handling the animals or by ingesting contami-
nated vegetables without cooking them. Only observed
in the northern hemisphere, and especially in central
Europe, Russia/Siberia, Central Asia, Western China,
north of Japan, and Alaska, AE is also one among the* Correspondence: kbardonnet@chu-besancon.fr
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distribution, and reproduction in any mediumrare parasitic diseases with a surgical treatment, because
of its “tumor-like” progression. The only available anti-
parasitic chemotherapy, i.e. high doses of albendazole
(ABZ) or mebendazole (MBZ) given continuously, is
only parasitostatic in this disease and the complete re-
section of the parasitic lesions is thus recommended
whenever possible [3,4]. In most of the cases, the para-
sitic lesions are initially located in the liver and may then
invade adjacent organs; however, true metastases may
also be seen in any organ or tissue. Extra-hepatic loca-
tions were already present at diagnosis in 34% of cases
in those cases recorded in the EurEchinoReg European
registry from 1982 to 2000 [5]. When the clinical symp-
toms at presentation are related to such extra-hepatic
locations, the diagnosis of AE is difficult and very often
it is confirmed after surgery on the pathological aspects
of the lesions and/or evidence of its parasitic nature bytral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Figure 1 Abdominal CT Scan (1982): alveolar echinococcosis
heterogeneous lesion of the right lobe of the liver, including a
large necrotic area (N) and a calcified area (C).
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dissemination is often associated with immune defi-
ciency of the host [8]. “Multi-organ AE” usually qualifies
cases with hepatic, pulmonary and cerebral locations
[9,10]; metastases to more than 2 organs/tissues are
extremely rare, either simultaneously or successively, in
immune-competent subjects. The involvement of several
organs is among the main causes of poor prognosis
[11,12]. We report here the case of an immune-
competent man with an AE discovered from a lung
metastasis in 1981 who had 5 different locations of the
disease, either simultaneously or successively, underwent
4 surgical operations on 6 different organs/tissues in 4
different locations, and who may nevertheless be consid-
ered cured from the disease after a unique follow-up of
more than 30 years.
Case report
The patient was a 38-year-old man who was admitted
into a local hospital of the region of Franche-Comté,
Eastern France, for the cure of an inguinal hernia. Sys-
tematic surgery pre-assessment disclosed by chance a
lung nodule which evoked pulmonary cancer. Thoracot-
omy with right upper lobectomy of the lung was per-
formed in January 1982 in Dijon University Hospital,
France, and the fortuitously discovered “tumor” was to-
tally removed. At the end of the operation, through the
diaphragm, the liver appeared to be enlarged, with a
modified structure, and the surgeon found a liver tumor
with a very hard consistency and a necrotic content of
100 mL which was aspirated; the diagnosis of AE was
thus evoked. Pathological examination of the lung
“pseudo-tumor” and of the surgical biopsies taken after
diaphragm incision, as well as the Computed Tomography
(CT) images obtained after the operation (Figure 1),
confirmed the diagnosis. As the patient wished to post-
pone the proposed liver resection, flubendazole was given
to the patient at a daily dosage of 9.0 g [13] until 1985
when he was eventually transferred to Besançon University
Hospital for radical liver resection and inclusion in
chemotherapy trials. The patient gave his consent to
be included in clinical research studies within the
framework of the study “Immunogenetics of AE in
humans” first, in 1994, then as part of the prospective
follow-up of AE patients in the FrancEchino Registry in
2003; both prospective cohort studies were approved by the
French legal ethical committee (CCPPRB/Franche-Comté:
comité consultatif pour la protection des personnes
en recherche biomédicale, for the region of Franche-
Comté); written informed consent was obtained from
the patient for publication of this report and any
accompanying images.
In May 1985, the specific serology tested by ELISA
using crude larval Em (EmC), and purified Em2 asantigens [14] was positive but in favor of a stable disease,
as well as the unchanged CT images which showed the
well-limited parasitic mass in the right liver with partial
necrosis and calcifications, and no involvement of the
biliary tree and/or hepatic and portal vessels. A right
hepatectomy with cholecystectomy was thus performed,
which removed a 1.45 kg parasitic tumor and was con-
sidered to be curative. Flubendazole was replaced by
MBZ at a daily dosage of 4.5 g from June to December
1985; then replaced by ABZ at a daily dosage of 400 mg
twice a day for 1 month followed by 2 week-
interruptions of treatment as recommended by the
manufacturer at that time (‘cyclic administration’) [3].
MBZ and ABZ were given within the framework of
WHO-coordinated therapeutic trials [15,16] and the pa-
tient had a regular prospective follow-up in Besançon
University Hospital WHO-clinical reference Centre.
ABZ treatment was spontaneously interrupted by the pa-
tient himself in June 1986, because of minor subjective
side-effects (digestive discomfort) without any biological
abnormalities. The previous treatment by MBZ was then
resumed. In May 1988, there were no clinical or bio-
logical abnormalities; ultra-sound examination only
showed the expected enlargement of the left liver usually
observed after right hepatectomy and the patient was
considered to be cured. As serology (ELISA using crude
larval antigen EmC, and purified Em2) was fully negative
and liver and lung imaging remained normal, MBZ was
thus stopped on May, 1988.
In April 1991, the patient was admitted into the Uni-
versity Hospital/AE reference Centre with a 3-month
long history of headache and right exophtalmia; visual
acuity, ocular mobility and eye fundus examinations
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serum was disclosed although abdominal and thoracic
imaging showed no recurrence of AE in the liver or ad-
jacent organs, or in the lung. Cerebral CT-scan and
Magnetic Resonance Imaging (MRI) disclosed 2 lesions:
one in the orbit and one in the right frontal lobe of the
brain. Both had a micro-polycystic hypodense structure,
with scattered calcifications. The surgical treatment con-
sisted of a subtotal resection of the lesion in the right
frontal lobe, the adjacent dura, the invaded part of the
eye lid and the eroded frontal bone. Brain and right or-
bital AE, with bone involvement was confirmed by the
pathological examination of the lesions which showed
necrotic and fibrous tissue filled with small cysts. Micro-
scopically, typical E multilocularis germinal layer and
protoscoleces were observed as well as periparasitic
epithelioid cells and the granulomatous infiltrate of
macrophages, lymphocytes and giant cells. ABZ at a
daily dosage of 800 mg, following the “cyclic” adminis-
tration as before, was introduced again in June 1991,
with recommendations of strict adherence to the treat-
ment. At the end of 1991, the situation was clinically
stable, with a marked regression of the remaining orbital
and cerebral lesions. Once again, upon the patient’s de-
mand, because of digestive discomfort, in March 1992,
ABZ was switched to MBZ; then the patient spontan-
eously interrupted his treatment in July 1992. ABZ was
resumed in October 1992 when the patient complained
of ptosis of the right eye and reduction of his visual acu-
ity, despite unchanged images of the brain and orbital
region. But once again the patient stopped his treatment
in February 1993.
At the beginning of 1994, thoracic CT-scan showed
AE recurrence, as a 45 mm in diameter-lesion in the
right pulmonary apex (Figure 2). From that date, the pa-
tient accepted to take ABZ at an increased dosageFigure 2 Thoracic CT Scan (1994): recurrent pulmonary lesion
of alveolar echinococcosis after the right lobectomy performed
in 1982.(20 mg/day/kg) and continuously, as suggested by the
recommendations of the WHO-Informal Working
Group on Echinococcosis for severe AE cases (1996
Guidelines). In February 1996, as AE seemed under con-
trol, the 52-yr old patient benefited from an elective left
hip prosthesis in that same local hospital he had been
admitted first in 1981. Because of an abnormal structure
of the bone disclosed by the surgeon, a pathological
examination was performed in Besançon University Hos-
pital on bone sections. Despite abnormalities compatible
with parasitic vesicles, formal AE diagnosis could not be
ascertained since no typical germinal layer was observed;
the inflammatory infiltrate could also be due to asso-
ciated arthritis; and no PCR could be performed retro-
spectively on the lesions because of technical issues.
Complete clinical and radiological assessment of possible
metastatic locations of the disease did not disclose any
other lesions. In 1999, the size of the pulmonary lesion
had markedly decreased (to 21 mm in diameter) and in
2000 serology (Em2 and EmC ELISA) was completely
negative. Since then, the patient has been in good health,
except for overweight (height: 178 cm; weight: 100 kg;
abdominal perimeter: 117 cm) and subjective complaints
such as headaches and pain in his left hip. Adherence to
ABZ treatment was good. Yearly imaging exams includ-
ing ultrasound examination and CT-scans did not show
any changes in the images. A Fluoro-DeoxyGlucose
(FDG)-Positron Emission Tomography (PET) combined
with Computed Tomography (CT) performed in 2003
showed the absence of FDG uptake by the lesions in all
organs, 1 h after FDG injection. Serology (Em2 and
EmC ELISA) remained negative and ABZ was thus with-
drawn definitively in April 2003. At last follow-up in
2011, there was no evidence of recurrence/relapse, as
evidenced by negative PET-CT with conventional and
delayed acquisition of the images 3 h after FDG injection
(Figure 3), and by negative Em2+ ELISA serology (Bor-
dier Affinity Products, Crissier, Switzerland) [17]. At that
time, serology was also assessed by E. multilocularis
western-blot (LD Bio, Lyon, France) [18] in parallel on
two sera: a sample frozen in 1987, and a freshly collected
sample. With the serum sampled in 1987, two bands at
7 kDa and 26-28 kDa were observed, while with the
serum collected in 2011 only binding to 26-28 kDa Echi-
nococcus antigens was observed. Disappearance of the
7 kDa band thus confirmed imaging and ELISA serology
results.
Discussion
In the 1970s, in the patients with AE, life expectancy
was estimated to be reduced by 18.2 and 21.3 years for
men and women respectively; by 2005 it was reduced by
approximately 3.5 and 2.6 years, respectively [19]. Con-
tinuous ABZ has greatly contributed to prolonged
Figure 3 Positron Emission Tomography combined with CT Scan (2011): no FluoroDeoxyGlucose uptake whatever the previously
involved organ.
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ered of poor prognosis in AE; a recent study on 387
French patients confirmed that it was actually associated
with higher AE-specific mortality [12]. Moreover, multiple
extra-hepatic locations of AE are usually associated with
immune suppression [8]. The history of the AE patient we
are reporting suggests that multi-organ involvement and
AE recurrence over time may occur in non-immune
suppressed patients despite an apparently “radical surgery”
which removed all visible AE lesions, and might be
favored by a poor adherence to the benzimidazole chemo-
therapy. It also shows, however, that combined surgery
and continuous administration of ABZ at high dosage
may allow patients to survive more than 30 years after
diagnosis despite multi-organ involvement.Occurrence of metastatic locations of AE lesions is one
of the hallmarks which justify the similarities between AE
and malignant tumors, as exemplified by the PNM classifi-
cation which parallels the TNM classification of tumors
[21]. Invasion of neighboring organs and tissues (“N” in the
PNM classification) by E. multilocularis progression from
the initial liver location results in secondary lesions in the
right lung through the diaphragm, in peritoneal and retro-
peritoneal cavities, hepatic pedicle, round ligament, right
kidney and adrenal gland, pancreas, stomach or spleen.
True metastases (“M” in the PNM classification) are mainly
observed in the lung (7% of cases) [5], more rarely brain
(3%), spleen (1%) [5] or bones (less than 1%) [6,22], in the
skin [23] muscle [24], heart [24,25], and in any possible
anatomical locations [2]. The clinical presentation of our
Bardonnet et al. Annals of Clinical Microbiology and Antimicrobials 2013, 12:1 Page 5 of 7
http://www.ann-clinmicrob.com/content/12/1/1patient combined all main 3 locations; the brain location
was associated with orbit, eye, and facial/cranial bone
involvement, which is per se very rare and was for that rea-
son published several years ago [26]. In addition, metastases
occurred along a 13-year period, from the patient’s inau-
gural presentation with a lung metastasis in 1981 to the last
discovery of another lung metastasis in 1993; meanwhile,
brain, eye and bone locations were disclosed. In otherwise
non-immune suppressed patients, genetic factors leading to
poor cellular immunity and a marked trend to immune
tolerance are statistically associated with the severity of AE,
which includes metastasis formation [27,28], e.g. HLA B8,
DR3, DQ2 haplotype; however, this ‘at risk’ haplotype was
not present in our patient which actually was HLA A11,
A10; B13, B41; DR7, DR13; DQ2, DQ3. The main risk
factor for disseminated AE is actually immune suppression.
First observations were reported after liver transplantation
for AE in patients who were not treated by benzimidazoles
after receiving the liver graft [29]. Increase in residual
extra-hepatic lesions as well as occurrence of brain or
spleen metastasis were observed in a European series of 45
transplanted patients [30]. In the 1990s, such observations
contributed to greatly reduce the indication of liver trans-
plantation to treat AE [3]. Since then, AE occurrence in
patients with kidney or heart transplantation has also been
reported [31,32]. Rapidly progressing AE was also observed
in AIDS [33,34] and it was suggested that pregnancy could
be a tolerogenic situation which may have favored occur-
rence of brain metastasis [35]. Within the recent years, de-
velopment of cancer chemotherapy and use of more potent
immune suppressive drugs as well as immune modulating
biological agents, especially anti-TNF compounds, have
contributed to an increase in the number of disseminated
and/or rapidly progressing “opportunistic AE” in patients
with cancer, hematological disorders or chronic inflamma-
tory diseases [7,36,37]. Our patient, however, all along his
clinical course, did not present any overt - spontaneous or
disease/treatment-related- immune suppression. There is
no reason either to think that he was infected by an un-
usually virulent strain of E. multilocularis: several patients
were diagnosed with slowly progressing, non-disseminated
AE within a 30 km-range from his residence; and recent
genetic analyses of E. multilocularis in the patient’s endemic
area do not favor major differences which might be respon-
sible for more or less aggressive potential of the various
strains [38]. Absence of the highly specific E. multilocularis
16-18 kDa band at Western Blot on the serum sampled in
1987, a few months before the first treatment withdrawal,
was compatible with the negative ELISA results at that
time, and thus with “inactive” lesions; however, “inactivity”
was only temporary, as the following evolution well
demonstrated.
First introduced in the pharmacopeia at the end of
1970s, benzimidazoles, although they do not kill E.multilocularis larvae, are the only drug available to treat
AE and, being able to prevent metacestode growth and
provided they are taken for life, have markedly contributed
to improve AE patients’ prognosis [11,12,19]. Albendazole,
taken at the appropriate dosage of at least 15 mg/kg/day
according a continuous schedule, is currently considered
as the drug of choice [4]. Bad adherence to treatment,
initial treatment with flubendazole which was later proved
inefficient in AE, iterative switches from ABZ to MBZ
because of side-effects, as well as insufficient dosage of
ABZ due to the “discontinuous” schedule of administra-
tion recommended during the 1980-1990s [3] may have
been the main reasons for repeated dissemination of AE
lesions in the reported patient’s. Adherence to treatment
is essential and bad adherence, or ABZ withdrawal
because of side-effects, have been shown to be crucial for
lesion recurrence in patients with residual lesions after
liver transplantation [20]. It is remarkable that, after
13 years of unreliable intake of the antiparasitic drugs
tainted with successive extra-hepatic metastases of the
disease, good adherence to ABZ treatment was followed
by the inactivation of the lesions, negative PET-CT images
and serology within 10 years, and a decision of definitive
treatment withdrawal. The relative ‘tolerance’ of physi-
cians in charge of the patient towards his bad adherence
to treatment may also have been encouraged by the over-
confidence of the surgeons about the complete resection
of the initial lung and liver lesions. In addition, the
absence of any reliability in the patient’s allegations
regarding last intake of the antiparasitic drug prevented
them to measure ABZ sulfoxide plasma levels, which is,
however, usually routinely performed in that reference
center; MBZ measurements were not available when the
patient switched to MBZ, which he did most of the time;
and lower bioavailability of MBZ is well known [3].
Difficulties to assess completeness of the surgical resection
and necessity to adjunct benzimidazoles even if resection
was considered to be curative, were stressed as early as
the 1980s [14,39] and were further highlighted by the
observations of recurrence after liver transplantation [30].
Measurement of ABZ levels and proper interpretation of
low levels of ABZ sulfoxide as evidence of bad adherence
to treatment are also essential in the follow-up of AE
patients [4].
It is fortunate that our patient is still alive 30 years after
the diagnosis of AE and 9 years after antiparasitic drug
withdrawal; this observation confirms the therapeutic
effectiveness of ABZ, despite its absence of parasitocidal
effect, and possible withdrawal of the drug in highly
selected subjects. Absence of FDG uptake at PET-CT
assessment and negative Em2+ ELISA serology in 2011
suggest an aborting evolution of the parasitic lesions
whatever the involved organ or tissue; persistence of
the 26-28 kDa band at Western Blot is likely related
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organs of the patient, as is often the case in AE patients
with aborted lesions [2]. The current recommendations
concern the “security margin” to be observed by the sur-
geons for the resection of AE lesions, similar to those
recommended in oncological surgery, as well as the 2-yr
ABZ continuous treatment which is mandatory in the so-
called “radically operated on” patients [4]. Following these
recommendations would have likely prevented the occur-
rence of the distant metastases and also radically changed
our patient’s quality of life.
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